Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial vir…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-01 |
|---|---|---|---|---|
| Real | — | $1.20 | $1.10 | $0.91 |
| Estimado | $1.51 | $1.14 | $1.03 | $0.85 |
| Sorpresa | — | +5.3% | +6.8% | +7.1% |
| Métrica | SNY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 77.2% | 57.4% | +19.8% |
| Operating Margin | 14.5% | -34.4% | +48.9% |
| Net Margin | 17.9% | -32.5% | +50.4% |
| FCF Margin | 16.5% | -12.6% | +29.1% |
| ROE | 10.9% | -39.2% | +50.1% |
| ROA | 6.2% | -30.9% | +37.1% |
| Current Ratio | 1.09 | 2.73 | -1.64 |
| Debt / Equity | 0.20 | 0.28 | -0.08 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 6.2% | — |
| ✓Flujo de caja operativo positivo | €10.8B | €9.1B |
| ✓Rentabilidad sobre activos al alza | 6.2% | 4.2% |
| ✓Caja operativa/activos supera al ROA | 8.5% | ROA 6.2% |
| ✗Menos deuda a largo plazo | 11.2% | 8.9% |
| ✗Mejor liquidez (ratio corriente) | 1.09 | 1.46 |
| ✓Sin aumentar el nº de acciones | 1,226M | 1,256M |
| ✓Margen bruto al alza | 77.2% | 75.7% |
| ✓Rotación de activos al alza | 0.34 | 0.31 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 16.5% |
| ✗ROCE > 10 % | 6.4% |
| ✓Ventas > 5 %/año (3 años) | 5.0% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 26.1% |
Sanofi cotiza a 40.61 USD y tiene una capitalización bursátil de $98.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud